Brief: Fulcrum Therapeutics Q2 Basic EPS USD -0.38
03/08/2023 12:01
Aug 03 (Reuters) - Fulcrum Therapeutics Q2 operating income USD -27.292 million. * Q2 net income USD -23.783 million * Q2 operating expenses USD 28.172 million * Q2 collaboration revenue USD 880 thousand
Recent news on Fulcrum Therapeutics
See all newsFulcrum down after announcing restructuring, plans to cut 85% jobs
Brief: Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Fulcrum
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Philip Morris
Fulcrum falls after discontinuing sickle cell drug program